Expression of E-cadherin in breast cancer and its clinical significance

doi:10.3877/cma.j.issn.1674-0807.2015.03.006

Abstract

Abstract:

Objective

To study the expression of epithelial cellular adhesion molecule (E-cadherin)in different molecular subtypes of breast cancer and its clinical significance.

Methods

A total of 303 cases of breast cancer treated with modified radical mastectomy were retrospectively collected in the First Affiliated Hospital, Henan University of Science and Technology from November 2009 to October 2014.The expressions of E-cadherin and HER-2 in breast cancer tissues were detected by immunohistochemical staining to analyze the expression pattern of E-cadherin in different molecular subtypes of breast cancer and its association with clinicopathological features of the patients.Numeration data was processed using χ² test or Fisher's exact test,correlation analysis was performed using Pearson method, and Logistic regression was used to analyze the independent factors in E-cadherin expression.

Results

The positive rates of E-cadherin and HER-2 in 303 cases of breast cancer were 71.9% (218/303) and 16.2% (49/303) respectively.E-cadherin expression was correlated with patients' age, menopausal status, TNM staging, and axillary lymph node metastasis (χ² =4.854,8.277,8.757,10.614,all P ＜0.050);and HER-2 expression was associated with histological grade(χ²=0.002,P＜0.050).Pearson correlation analysis showed that E-cadherin was positively correlated with HER-2, ER, and PR in breast cancer tissue (r=0.135,0.206,0.135, P=0.019,0.000,0.019), and not correlated with Ki67.HER-2 was negatively correlated with ER and PR (r=-0.160, -0.118, P=0.005,0.040), and positively correlated with Ki67 (r=0.228, P=0.000).Logistic regression showed that patients'age, tumor size, and TNM staging, clinico pathological and HER-2 and ER were molecular pathological factors influencing E-cadherin expression in breast cancer.There was a significant difference in E-cadherin expression between different molecular subtypes of breast cancer (χ² = 24.816, P = 0.000).The positive rate of E-cadherin expression was 51.3% in triple-negative breast cancer (TNBC), significantly lower than that in luminal B or HER-2-riched (all P ＜0.008).

Conclusion

The deficiency of E-cadherin expression is associated with the biological behaviors of invasion and metastasis in TNBC, while HER-2 and ER may be involved in the regulatory mechanism of E-cadherin expression deficiency.

Key words: Breast neoplasms, E-cadherin, Molecular subtypes, Epidermal growth factor receptor

Miao Deng, Jiangbo Liu, Qipeng Liu, Dongfeng Ge, Dengting Chen, Dechun Liu, Luqi Xing. Expression of E-cadherin in breast cancer and its clinical significance[J]. Chinese Journal of Breast Disease(Electronic Edition), 2015, 09(03): 182-187.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2015.03.006

https://zhrxbzz.cma-cmc.com.cn/EN/Y2015/V09/I03/182

Figures/Tables 8

References 17

[1]	陈万青, 郑荣寿, 曾红梅, 等.2011 年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2015,24(1):1-10.
[2]	Savci-Heijink CD, Halfwerk H, Hooijer GK, et al.Retrospective analysis of metastatic behaviour of breast cancer subtypes[J].Breast Cancer Res Treat, 2015,150 (3):547-557.
[3]	Goldhirsch A, Winer EP, Coates AS, et al.Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J].Ann Oncol, 2013,24(9):2206-2223.
[4]	Paredes J,Figueiredo J,Albergaria A,et al.Epithelial E-and P-cadherins: role and clinical significance in cancer [J].Biochim Biophys Acta,2012,1826:297-311.
[5]	Ye Y, Tian H, Lange AR, et al.The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin [J].Oncogene,2013,32(13):1702-1713.
[6]	孙弢,姚宇锋, 龚建平, 等.E-钙黏蛋白在三阴性乳腺癌组织中的表达[J].肿瘤基础与临床,2014,27(1):8-10.
[7]	Guo J, Liu Z, Zhang G, et al.Efficiency and safety of trastuzumab plus chemotherapy in Her-2 overexpressing metastatic breast cancer patients[J].Chinese-German J Clin Onwl,2014,13(12):555-559.
[8]	Mahler-Araujo B, Savage K, Parry S, et al.Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype[J].J Clin Pathol,2008,61(5):615-620.
[9]	Wolff AC, Hammond ME, Hicks DG, et al.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J].J Clin Oncol,2013,31(31):3997-4013.
[10]	王新昭, 左文述, 刘琪, 等.2013 年St.Gallen 乳腺癌会议国际专家共识荟萃[J].中华肿瘤防治杂志, 2013,20(23):1859-1864.
[11]	Goldhirsch A, Wood WC, Coates AS, et al.Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol, 2011,22(8):1736-1747.
[12]	赵晓辉, 郝春芳,王忱,等.三阴性乳腺癌的临床病理学特征及预后分析[J/CD].中华乳腺病杂志:电子版, 2009,3(6):590-599.
[13]	Bauer KR, Brown M, Cress RD, et al.Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER-2-negative invasive breast cancer, the socalled triple-negative phenotype[J].Cancer, 2007,109(9):1721-1728.
[14]	Thiery JP.Epithelial-mesenchymal transitions in tumour progression[J].Nat Rev Cancer,2002,2(6):442-454.
[15]	孔德娣.E-钙黏附蛋白表达与乳腺癌及三阴性乳腺癌预后的相关性研究[J/CD].中华乳腺病杂志:电子版, 2013,7(1):43-46.
[16]	Fearon ER.Connecting estrogen receptor function,transcriptional repression, and E-cadherin expression in breast cancer[J].Cancer Cell,2003,3(4):307-310.
[17]	Fujita N, Jaye DL, Kajita M, et al.MTA3, a Mi-2/NuRD complex subunit,regulates an invasive growth pathway in breast cancer[J].Cell,2003,113(2):207-219.

变量	变量分类及赋值
E-cadherin表达	阴性=1,阳性=2
年龄	＜50岁=1,≥50岁=2
月经状态	绝经前=1,绝经后=2
组织学分级	Ⅰ级=1,Ⅱ级=2,Ⅲ级=3
腋窝淋巴结转移	N₀=1,N₁=2,N₂=3,N₃=4
肿瘤直径	T₁=1,T₂=2,T₃=3
TNM分期	Ⅰ期=1,Ⅱ期=2,Ⅲ期=3,Ⅳ期=4

变量	变量分类及赋值
E-cadherin表达	阴性=1,阳性=2
年龄	＜50岁=1,≥50岁=2
月经状态	绝经前=1,绝经后=2
组织学分级	Ⅰ级=1,Ⅱ级=2,Ⅲ级=3
腋窝淋巴结转移	N₀=1,N₁=2,N₂=3,N₃=4
肿瘤直径	T₁=1,T₂=2,T₃=3
TNM分期	Ⅰ期=1,Ⅱ期=2,Ⅲ期=3,Ⅳ期=4

变量	变量分类及赋值
E-cadherin表达	阴性=1,阳性=2
HER-2表达	阴性=1,阳性=2
ER表达	阴性=1,阳性=2
PR表达	阴性=1,阳性=2
Ki67表达	阴性=1,阳性=2

变量	变量分类及赋值
E-cadherin表达	阴性=1,阳性=2
HER-2表达	阴性=1,阳性=2
ER表达	阴性=1,阳性=2
PR表达	阴性=1,阳性=2
Ki67表达	阴性=1,阳性=2

临床病理特征	例数	E-cadherin(例)		χ²值	P值	HER-2(例)		χ²值	P值
临床病理特征	例数	阴性	阳性	χ²值	P值	阴性	阳性	χ²值	P值
年龄
＜50岁	144	49	95	4.854	0.028	125	19	1.794	0.180
≥50岁	159	36	123	4.854	0.028	129	30	1.794	0.180
月经状态^a
绝经前	170	59	111	8.277	0.004	142	28	0.017	0.896
绝经后	132	26	106	8.277	0.004	111	21	0.017	0.896
组织学分级^b
Ⅰ级+Ⅱ级	210	47	163	2.295	0.130	167	43	6.786	0.009
Ⅲ级	63	20	43	2.295	0.130	59	4	6.786	0.009
肿瘤直径^c
≤2cm	97	23	74	0.001	0.974	82	15	0.002	0.962
＞2cm	153	36	117	0.001	0.974	129	24	0.002	0.962
TNM分期^d
Ⅰ期	57	15	42	8.757	0.033	50	7	0.731	0.866
Ⅱ期	121	22	99			101	20
Ⅲ期	45	10	35			38	7
Ⅳ期	27	12	15			22	5
淋巴结转移
N₀	146	45	101	10.614	0.014	127	19	4.084	0.253
N₁	79	15	64			61	18
N₂	52	12	40			45	7
N₃	26	13	13			21	5

Please choose a citation manager

Content to export